wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q52661543-C5DF0A97-0576-4677-8AB3-2461C5BEF322
Q52661543-C5DF0A97-0576-4677-8AB3-2461C5BEF322
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52661543-C5DF0A97-0576-4677-8AB3-2461C5BEF322
Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America.
P2860
Q52661543-C5DF0A97-0576-4677-8AB3-2461C5BEF322
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52661543-C5DF0A97-0576-4677-8AB3-2461C5BEF322
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
3ed1afce6a90c17de1763b67852a1f0f66329627
P2860
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.